



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No. : 10/715,130 Confirmation No. : 1917  
Applicant : MATTHIAS STRAUB, et al.  
Filed : November 18, 2003  
TC/A.U. : 1614  
Examiner : To Be Assigned  
Docket No. : 029300.51815US  
Customer No. : 23911  
Title : LIQUID PHARMACEUTICAL FORMULATIONS  
CONTAINING 3,7-DIAZABICYCLO [3,3,1]NONANE  
COMPOUNDS AND METHODS OF TREATMENT  
RELATING TO ANTI-ARRHYTHMIC EVENTS

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97 and 1.98**

**Mail Stop Missing Parts**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

**STATEMENT OF RELEVANCE**

The relevance of these references to the subject matter of the present invention is given in the Background of the Invention in the specification of the present invention.


An English abstract and a U.S. counterpart of European Patent No. 0103833 are submitted herewith.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


Respectfully submitted,

April 13, 2004

  
\_\_\_\_\_  
J. D. Evans  
Registration No. 26,269

CROWELL & MORING, LLP  
Intellectual Property Group  
P.O. Box 14300  
Washington, DC 20044-4300  
Telephone No.: (202) 624-2500  
Facsimile No.: (202) 628-8844

JDE/ms



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**Complete if Known**

Application Number	10/715,130
Filing Date	November 18, 2003
First Named Inventor	MATTHIAS STRAUB
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	029300.51815US

## FOREIGN PATENT DOCUMENTS

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.